BPTH 5.2's Bio-Path Reports Notice Of Allowance For Strategic Patent For Prexigebersen In Combo With Front Line Cytidine Analogues Or Bcf-Abl Tyrosine Kinase Inhibitors In a Variety Of Cancers Benzinga
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.